Mepazine hydrochloride (Pecazine hydrochloride) is a potent and selective inhibitor of MALT1 protease, with IC50 values of 0.83 μM for GSTMALT1 full length and 0.42 μM for GSTMALT1 aa 325-760. It effectively suppresses the activation of the NF-kB pathway specifically in activated B cell subtype of diffuse large B cell lymphoma (ABC-DLBCL) cells and makes […]

Mepazine hydrochloride (Pecazine hydrochloride) is a potent and selective inhibitor of MALT1 protease, with IC50 values of 0.83 μM for GSTMALT1 full length and 0.42 μM for GSTMALT1 aa 325-760. It effectively suppresses the activation of the NF-kB pathway specifically in activated B cell subtype of diffuse large B cell lymphoma (ABC-DLBCL) cells and makes […]

Mepazine hydrochloride (Pecazine hydrochloride) is a potent and selective inhibitor of MALT1 protease, with IC50 values of 0.83 μM for GSTMALT1 full length and 0.42 μM for GSTMALT1 aa 325-760. It effectively suppresses the activation of the NF-kB pathway specifically in activated B cell subtype of diffuse large B cell lymphoma (ABC-DLBCL) cells and makes […]

Metergoline is a serotonin (5-HT) receptor and dopamine receptors antagonist, with pKis of 8.64, 8.75 and 8.75 for 5-HT2A, 5-HT2B and 5-HT2C, respectively. Metergoline is a high-affinity ligand for the h5-HT7 receptor, with a Ki of 16 nM. Metergoline is also a reversible neural Na+ channels inhibitor. Metergoline is commonly used for the research of […]

Senexin B (SNX2-1-165, BCD-115) is a potent and selective small-molecule inhibitor of CDK8/19, with Kd values of 140 nM for CDK8 and 80 nM for CDK19. It significantly slows tumor growth and inhibits Triple-Negative Breast Cancer (TNBC) xenograft tumor progression.

STC-15 is an oral, small-molecule inhibitor of RNA methyltransferase METTL3. It inhibits tumor growth through the activation of anti-cancer immune responses associated with increased interferon signaling and synergizes with T-cell checkpoint blockade.

STC-15 is an oral, small-molecule inhibitor of RNA methyltransferase METTL3. It inhibits tumor growth through the activation of anti-cancer immune responses associated with increased interferon signaling and synergizes with T-cell checkpoint blockade.

STC-15 is an oral, small-molecule inhibitor of RNA methyltransferase METTL3. It inhibits tumor growth through the activation of anti-cancer immune responses associated with increased interferon signaling and synergizes with T-cell checkpoint blockade.

STC-15 is an oral, small-molecule inhibitor of RNA methyltransferase METTL3. It inhibits tumor growth through the activation of anti-cancer immune responses associated with increased interferon signaling and synergizes with T-cell checkpoint blockade.

T025 is as an orally available and potent inhibitor of Cdc2‐like kinases (CLKs) with an IC50s of 0.93 nM, 1 nM, 14 nM, 1.5 nM for CLK1, CLK2, CLK3, DYRK1B respectively. It exhibits anti‐tumor efficacy and can be used in MYC‐driven cancer research.